Abstract:1045 Objectives: The overall aim of this study was to validate I-131-PD-L1 SPECT tumor imaging and therapy, especially patients who has poor response to anti PD-L1 mAb therapy based on successful preparation of the probe with excellent stability. Methods: Anti-PD-L1(experimental probe) and IgG (control) were radiolabeled with iodine-131 (I-131-PD-L1, I-131-IgG) and were characterized in vitro, respectively. The stability of the probe and 4T1 cell up-taking after preparation of I-131-PD-L1 was prepared. Ability ofI-131-PD-L1 targeting to tumor was verified by bioditribution and SPECT, including blockade, I-131-IgG and I-131-PD-L1 (human). Expression of PD-L1 in tumor was tested by immunohistochemistry (IHC). To verify their therapeutic value, the study was recorded volume of tumor and their death in groups:I-131-PD-L1+ PD-L1 mAb, I-131-PD-L1, PD-L1 mAb and NS control. The side effects by I-131-PD-L1 and PD-L1 mAb were observed. Results: I-131-PD-L1 was successfully prepared and collected into EP tubes after purification by PD10 Column, with radiochemical yield (RCY): 80.21%±2.98% (n=5) and radiochemical purity (RCP): 96.51%±1.10% (n=5). The probe kept excellent stability with RCP>92% at 72 hours in vitro (n=6), RCP>90% in vivo at 24 hours and RCP>80% in vivo at 72 hours (n=3). The up-taking ratio peaked at 2 hours with 3.18%±0.86% (n=6). Ratio of T/M and T/B reached at 8.66±1.46 and 6.31±1.95 in biodistribution at 120 hours and I-131-PD-L1 in tumor was significantly suppressed (F=17.279, P=0.006) in blockade biodistribution. The breast tumor could be imaged by SPECT at 24 hours and the tumor gradually showed clearer at 48 hours and 72 hours post-injection and never be imaged in I-131-IgG (mouse), I-131-PD-L1 (blockade) and I-131-PD-L1 (human) at 72 hours. I-131-PD-L1+mAb could significantly suppress tumor growth than others groups; the median survivals of I-131-PD-L1+mAb was greatly longer than other groups, and the last one in combined therapy group survived till the 41st day which was better than mice in other groups. In the second PD-L1 mAb therapy (10 μg/g) which performed at 96 hours after the first mAb therapy (10 μg/g), we observed that 9/12 mice displayed serious adverse drug reaction of respiratory system, and died in 12 hours. Hepatorenal functions would keep normal at 7.4 MBq (200 μCi), but weight of mice dramatically descended due to poor appetite. Conclusions: I-131-PD-L1 could noninvasively monitor the expression of PD-L1 in breast tumor by SPECT scan. The probes could dramatically suppress tumor and prolong survival time. Key Words: SPECT; PD-L; Iodine-131; Theranostic probe; Molecular imaging

Improved Resection and Prolonged Overall Survival with PD-1-IRDye800CW Fluorescence Probe-Guided Surgery and PD-1 Adjuvant Immunotherapy in 4T1 Mouse Model

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-64Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy

Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition.

Radioimmunoimaging and Targeting Treatment in an Immunocompetent Murine Model of Triple-Negative Breast Cancer Using Radiolabeled Anti-Programmed Death-Ligand 1 Monoclonal Antibody

Experimental Study on Radioiodine Labeled Anti-PD-L1 Monoclonal Tibody As Novel Tumor Immunosuppressive Agent Imaging Probe

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy

Immuno-SPECT/PET Imaging with Radioiodinated Anti-Pd-l1 Antibody to Evaluate PD-L1 Expression in Immune-Competent Murine Models and PDX Model of Lung Adenocarcinoma.

Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature

Improved Debulking of Peritoneal Tumor Implants by Near-Infrared Fluorescent Nanobody Image Guidance in an Experimental Mouse Model

Sensitive and Quantitative in Vivo Analysis of PD-L1 Using Magnetic Particle Imaging and Imaging-Guided Immunotherapy

SERS surgical navigation with postsurgical immunotherapy of local microtumors and distant metastases for improved anticancer outcomes

Abstract 2746: PET-CT/FACS Platform to Detect the Biodistribution of Radioisotope 89zr PD-1 Inhibitor in Syngeneic Tumor Models

1197 Site-specific Anti-Pd-1-irgd Peptide Conjugate Boosts Antitumor Efficacy Via Enhancement of T Cell Penetration and Engagement

Fluorescence Lifetime Imaging Enables In vivo Quantification of PD-L1 Expression and Inter-tumoral Heterogeneity

Intraoperative Identification and Guidance of Breast Cancer Microfoci Using Ultrasound and Near-Infrared Fluorescence Dual-Modality Imaging

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors

Intraoperative evaluation of tumor margins using a TROP2 near-infrared imaging probe to enable human breast-conserving surgery

Research Progress of PD-1/PD-L1 Targeted Radionuclide Molecular Probes in Tumor Immunotherapy

1241 Sustained Localized Delivery of Anti-PD-1 to Tumor Draining Lymph Nodes Increases Survival and Reverses Immunosuppression in Murine Glioblastoma Models

Development and Preclinical Evaluation of a Near-Infrared Fluorescence Probe Based on Tailored Hepatitis B Core Particles for Imaging-Guided Surgery in Breast Cancer